healthliberal
Psoriasis Treatment: Age and BMI Matter
Thursday, December 26, 2024
The study included 74 people with psoriasis who took deucravacitinib for 16 weeks. Researchers checked to see if the treatment helped improve their skin condition. They found that older people and those with a lower BMI were more likely to see improvements. This suggests that these factors might be important in predicting how well someone will respond to deucravacitinib.
It's interesting to note that this study was done in a real-world setting, not just in a lab. This makes the findings more relevant to how the drug might work in everyday life. However, it's important to remember that everyone is different, and what works for one person might not work as well for another.
Actions
flag content